U.S. Department of Transportation

Proposed Rule Changes By the Department of Transportation

Proposed Rule Changes By the Department of Transportation

U.S. Department of TransportationOn Monday January 23, 2017, The Department of Transportation (DOT) is proposing to amend its drug-testing program regulation to add four opioids.

  • hydrocodone,
  • hydromorphone,
  • oxymorphone, and
  • oxycodone to its drug-testing panel;

It also proposes to add methylenedioxyamphetamine (MDA) as an initial test analyte; and remove methylenedioxymethamphetamines, (MDEA) as a confirmatory test analyte.

The proposed revision of the drug testing panel is intended to synchronize with the revised Mandatory Guidelines established by the U.S. Department of Health and Human Services (HHS).  The effective date of these changes is October 1, 2017.  DOT is required by the Omnibus Transportation Employees Testing Act  to follow the HHS requirements for the testing procedures, protocols and drugs for which are screened:

 

The NPRM proposes to:

  1. Align DOT regulated drug testing with the Department of Health and Human Services (HHS) laboratory drug testing requirements,
  2. Provide clarification to certain existing drug-testing requirements,
  3. Remove outdated information from the current regulation, and
  4. Remove the requirement for employers and C/TPAs to submit blind specimens.

 

Other Department Of Transportation proposals:

  • Modify specific definitions to make certain definitions consistent with those of HHS;
  • Add emphasis to an existing Part 40 provision that excludes DNA testing of urine specimens;
  • Allow federal agencies to authorize collection of an alternate specimen (e.g., oral fluid) when a donor in their program is unable to provide enough urine specimen (45ml) at the collection site
  • Add clarification to the term “prescription”;
  • Modify sections related to how MROs verify test results related to semi-synthetic opioids;
  • Require collector, alcohol testing technicians, and substance abuse professionals to subscribe to ODAPC’s list serve;
  • Remove a list of Substance Abuse Professional certification organizations from rule text and instead maintain the list on ODAPC’s web site;
  • Include a provision to exclude program participants from using DOT-branded items on their websites, publications, etc.;
  • Remove outdated compliance dates;
  • Make various technical amendments.

 

For more information follow these links:

The Federal Register NPRM

FR_20170123_NPRM_Opioids.pdf

Leave a Reply

American Drug Testing Inc. 2016 © | (800)-488-5350